Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Goodwill (2016 - 2025)

Historic Goodwill for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $8.1 million.

  • Anika Therapeutics' Goodwill rose 515.94% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 515.94%. This contributed to the annual value of $7.1 million for FY2024, which is 589.09% down from last year.
  • As of Q3 2025, Anika Therapeutics' Goodwill stood at $8.1 million, which was up 515.94% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Goodwill registered a high of $8.1 million during Q2 2021, and its lowest value of $6.7 million during Q3 2022.
  • Its 5-year average for Goodwill is $7.6 million, with a median of $7.5 million in 2023.
  • Its Goodwill has fluctuated over the past 5 years, first crashed by 7619.96% in 2021, then surged by 960.54% in 2025.
  • Anika Therapeutics' Goodwill (Quarter) stood at $7.8 million in 2021, then decreased by 5.68% to $7.3 million in 2022, then grew by 3.16% to $7.6 million in 2023, then dropped by 5.89% to $7.1 million in 2024, then grew by 13.0% to $8.1 million in 2025.
  • Its Goodwill was $8.1 million in Q3 2025, compared to $8.1 million in Q2 2025 and $7.4 million in Q1 2025.